Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 5, 2008, Pages 446-452

  Gianoukakis, Andrew G ^a   Smith, Terry J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Autoimmune; Cytokines; Graves' disease; Ophthalmopathy; Thyroid

Indexed keywords

CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN C RECEPTOR; THYROTROPIN RECEPTOR;

AUTOIMMUNITY; CYTOKINE PRODUCTION; DISEASE MODEL; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; IMMUNOPATHOGENESIS; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; X CHROMOSOME;

ANIMALS; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS;

EID: 53549135184     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32830eb8ab     Document Type: Review

References (76)

1. Guameri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes2007; 14:398-409.
2. Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86:930-934.
3. Kula D, Bednarczuk T, Jurecka-Lubieniecka B, et al. Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1 *07. Thyroid 2006; 16:447-453.
4. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12:881-922.
5. Smith TJ, Sciaky D, Phipps RP, Jennings TA. CD40 expression in human thyroid tissue: evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. Thyroid 1999; 9:749-755.
6. Metcalfe RA, Mclntosh RS, Marelli-Berg F, et al. Detection of CD40 on human thyroid follicular cells: analysis of expression and function. J Clin Endocrinol Metab 1998; 83:1268-1274.
7. Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol 1998; 274:C707-C714.
8. Feldon SE, Park DJ, O'Loughlin CW, et al. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2005; 46:3913-3921.
9. Cao HI, Wang HS, Zhang Y, et al. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem 1998; 273:29615-29625.
10. Tomer Y, Concepcion E, Greenberg DA. A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid 2002; 12:1129-1135.
11. Kim TY, Park YJ, Hwang JK, et al. A C/T polymorphism in the 5′-untranslated region of the CD40 gene is associated with Graves' disease in Koreans. Thyroid 2003; 13:919-925.
12. Mukai T, Hiromatsu Y, Fukutani T, et al. A C/T polymorphism in the 5′-untranslated region of the CD40 gene is associated with later onset of Graves' disease in Japanese. Endocr J 2005; 52:471-477.
13. Jacobson EM, Huber AK, Akeno N, et al. A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun 2007; 8:205-214.
14. Jacobson EM, Concepcion E, Oashi T, Tomer Y. A Graves' diseaseassociated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 2005; 146:2684-2691.
15. Harigai M, Hara M, Nakazawa S, er al. Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes. J Rheumatol 1999; 26:1035-1043.
16. Gribben JG, Freeman GJ, Boussiotis VA, et al. CTLA4 mediates antigenspecific apoptosis of human T cells. Proc Natl Acad Sci U S A 1995; 92:811-815.
17. Waterhouse P, Penninger JM, Timms E, et al. Lymphoprolrferatrve disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-988.
18. Ueda H, Howson JM, Esposho L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506-511.
19. Ban Y, Tozaki T, Taniyama M, et al. Association of a CTLA-43′ untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population. Autoimmunity 2005; 38:151-153.
20. Petrone A, Giorgi G, Galgani A, et al. CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid 2005; 15:232-238.
21. Han S, Zhang S, Zhang W, et al. CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis. Hum Immunol 2006; 67:618-626.
22. Chen PL, Fann CS, Chang CC, et al. Family-based association study of cytotoxic T-lymphocyte antigen-4 with susceptibility to Graves' disease in Han population of Taiwan. Genes Immun 2008; 9:87-92.
23. Kawoura FK, Akamizu T, Awata T, et al. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a metaanalysis. J Clin Endocrinol Metab 2007; 92:3162-3170.
24. Han SZ, Zhang SH, Li R, et al. The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. Int J Immunogenet 2006; 33:281-287.
25. Saverino D, Brizzolara R, Simone R, et al. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007; 123:190-198.
26. Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53:3020-3023.
27. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan altete of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 2004; 89:5862-5865.
28. Heward JM, Brand OJ, Barrett JC, et al. Association of PTPN22 haplotypes with Graves' disease. J Din Endocrinol Metab 2007; 92:685-690.
29. Gjorloff-Wingren A, Saxena M, Williams S, et al. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 1999; 29:3845-3854.
30. Cloutier JF, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999; 189:111-121.
31. Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37: 1317-1319.
32. Yu X, Sun JP, He Y, et al. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci U S A 2007; 104:19767-19772. Expression and function of LYP, a negative regulator of T cell activation, may represent an important modulator of autoimmunity.
33. Simmonds MJ, Howson JM, Heward JM, et al Regression mapping of association between the human leukocyte antigen region and Graves disease. Am J Hum Genet 2005; 76:157-163.
34. Invernizzi P, Miozzo M, Selmi C, et al. X chromosome monosomy: a common mechanism for autoimmune diseases. J Immunol 2005; 175:575-578.
35. Ozcelik T, Uz E, Akyerli CB, et al. Evidence from autoimmune thyroiditis of skewed X-chromosome inactivation in female predisposition to autoimmunity. Eur J Hum Genet 2006; 14:791-797.
36. Yin X, Latif R, Tomer Y, Davies TF. Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci 2007; 1110:193-200.
37. Brix TH, Knudsen GP, Kristiansen M, et al. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab 2005; 90:5949-5953.
38. Flynn JC, Gilbert JA, Meroueh C, et al. Chronic exposure in vivo to thyrotropin receptor stimulating monoclonal antibodies sustains high thyroxine levels and thyroid hyperplasia in thyroid autoimmunity-prone HLA-DRB1*0301 transgenic mice. Immunology 2007; 122:261-267.
39. Land KJ, Gudapati P, Kaplan MH, Seetharamaiah GS. Differential requirement of signal transducer and activator of transcription-4 (Stat4) and Stat6 in a thyrotropin receptor-289-adenovirus-induced model of Graves' hyperthyroidism. Endocrinology 2006; 147:111-119.
40. Kaneda T, Honda A, Hakozaki A, et al. An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology 2007; 148:2335-2344.
41. Baker G, Mazziotti G, von Ruhland C, Ludgate M. Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy. Endocrinology 2005; 146:835-844.
42. McLachlan SM, Nagayama Y, Pichurin PN, et al. The link between Graves' disease and Hashimoto's thyroiditis: a role for regulatory T cells. Endocrinology 2007; 148:5724-5733.
43. Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 2005; 175:1310-1319.
44. Chen B, Tsui S, Boeglin WE, et al. lnterleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem 2006; 281:18296-18306.
45. Han R, Smith TJ. Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. J Immunol 2005; 174:3072-3079.
46. Gianoukakis AG, Douglas RS, King CS, et al. Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology 2006; 147:1941-1949.
47. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001; 86:5008-5016.
48. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 2002; 168:942-950.
49. Antonelli A, Rotondi M, Ferrari SM, et al. Interferon-gamma- inducible alphachemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006; 91:614-620.
50. Romagnani P, Rotondi M, Lazzeri E, et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 2002; 161:195-206.
51. Antonelli A, Fallahi P, Rotondi M, et al. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154:651-658.
52. Crescioli C, Cosmi L, Borgogni E, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 2007; 195:145-155.
53. Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003; 170:6348-6354.
54. Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 2007; 178:3281-3287. IGF-1R expressing T cells are overrepresented in patients with Graves' disease compared with controls. T cell activation through IGF-1 R enhances survival, proliferation and results in a disproportionate increase in CD45RO+IGF-1R+ memory T cells.
55. Aust G, Kamprad M, Lamesch P, Schmucking E. CXCR6 within T-helper (Th) and T-cytotoxic (Tc) type 1 lymphocytes in Graves' disease (GD). Eur J Endocrinol 2005; 152:635-643.
56. Roura-Mir C, Catalfamo M, Cheng TY, et al. CD1a and CD1c activate intrathyroidal T cells during Graves' disease and Hashimoto's thyroiditis. J Immunol 2005; 174:3773-3780.
57. Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy. Thyroid 2002; 12:193-195.
58. Feliciello A, Porcellini A, Ciullo I, et al. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 1993; 342:337-338.
59. Zhang L, Baker G, Janus D, et al. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci 2006; 47:5197-5203.
60. Agretti P, De Marco G, De Servi M, et al. Evidence for protein and mRNA TSHr expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation. Eur J Endocrinol 2005; 152:777-784.
61. Feldon SE, O'Loughlin CW, Ray DM, et al. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol 2006; 169:1183-1193.
62. Kumar S, Leontovich A, Coenen MJ, Bahn RS. Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab 2005; 90:4730-4735.
63. El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007; 92:1769-1772. In this uncontrolled study, treatment with rituximab sustained remission in a subset of uncomplicated Graves' disease patients with low TSI titers.
64. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156:33-40. An open label nonrandomized pilot study of patients with mild-to-moderate TAO showing that rituximab positively affects the clinical course of TAO when compared with glucocorticoid therapy.
65. Kung AW, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 1996; 6:381-384.
66. Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004; 89:5910-5915.
67. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005; 90:841-848.
68. Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebocontrolled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 2006; 91:4817-4824.
69. Chang TC, Liao SL. Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006; 29:413-422.
70. Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest 1993; 23:10-17.
71. Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy. J Clin Endocrinol Metab 2003; 88:4246-4250.
72. Simmonds MJ, Heward JM, Howson JM, et al. A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease. Genes Immun 2004; 5:267-273.
73. Shiau MY, Huang CN, Yang TP, et al. Cytokine promoter polymorphisms in Taiwanese patients with Graves' disease. Clin Biochem 2007; 40:213-217.
74. Quadbeck B, Stucke M, Eckstein AK, et al. Dysregulation of TNF/TNFR superfamily members: a systemic link between intra- and extrathyroidal manifestations in Graves' disease. Scand J Immunol 2006; 64:523-530.
75. Pandaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005; 19:1286-1289.
76. Durrani OM, Reuser TO, Murray Pt. Infliximab: a novel treatment for sightthreatening thyroid associated ophthalmopathy. Orbit 2005; 24:117-119.